Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a

Zhou, Yi; Wang, X. H.; Hong, Guo-hu; Zhu, Yan; Zhang, X. Q.; Ying, Hanjie; Mao, Qing

doi:10.1111/j.1365-2893.2010.01373.x

Cited by 19 publications

(26 citation statements)

References 22 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Both of the mutations showed association with viral clearance in SVR patients. Association of mutations outside PKR with treatment outcome have also been reported by Zhou et al, [28] particularly in genotype 1b. El-Shamy et al [29], have identified a region downstream to ISDR named as IFN/Ribavirin resistance determining region (IRRDR) in genotype 1b.…”

Section: Discussionsupporting

confidence: 59%

Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population

Mansoor

Ali

Sabah

et al. 2013

Virol J

View full text Add to dashboard Cite

BackgroundHepatitis C virus (HCV) is a major cause of liver cirrhosis and hepatocellular carcinoma and infects about 3% world population. Response to interferon therapy depends upon the genotype of the virus and factors associated with the host. Despite a good response to interferon therapy, a considerable number of genotype 3a infected patients remains unalleviated.ResultsIn total forty-nine patients including twenty-five non-responders (non-SVR) and twenty-four responders (SVR) were recruited. Patients were tested for viral status at different intervals and the isolated RNA was sequenced for the NS5A region in both groups. The comparison of PKRBD of HCV between the SVR and non-SVR patients did not confirm any significant difference in the number of mutations. However, when the sequence downstream to the PKRBD of NS5A was compared, two important statistically significant mutations were observed; at positions 2309 (Ala to Ser) and 2326 (Gly to Ala). These mutations were then analysed for tertiary protein structure and important structural changes were observed. Statistically significant difference was also observed when age groups of patients were compared; younger patients showed better response than the older ones.ConclusionsThe region between PKRBD and IRRDR may be important for prediction of response to IFN therapy for genotype 3a. ISDR and PKRBD have not shown any involvement in treatment response. Further functional analyses of these findings can help in understanding the involvement of the NS5A region in interferon treatment of HCV-3a infected patients.

show abstract

Section: Discussionsupporting

confidence: 59%

Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population

Mansoor

Ali

Sabah

et al. 2013

Virol J

View full text Add to dashboard Cite

show abstract

“…Six trials assessed treatment response in patients infected with HCV-6 compared with those infected with HCV-1 [18,19,21,27,29,30]. Among these, 3 were direct comparisons of response to antiviral therapy by HCV-6 versus HCV-3 and/or HCV-2 patients.…”

Section: Resultsmentioning

confidence: 99%

“…The modified process employed for study search and selection is summarized in figure 1. After the titles were screened and abstracts read, 193 studies were removed based on exclusion criteria and 14 potentially eligible articles included [17,18,19,20,21,22,23,24,25,26,27,28,29,30]. Among these studies, some studies were only included on the treatment efficacy of PEG-IFN+RBV for HCV-6 in a previous study [31].…”

Section: Resultsmentioning

confidence: 99%

Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis

Thông¹,

Poovorawan²,

Tangkijvanich

et al. 2015

Intervirology

View full text Add to dashboard Cite

Objectives: We conducted a systematic review and meta-analysis of the influence of host and viral factors on the sustained virologic response (SVR) in hepatitis C virus genotype 6 (HCV-6) patients treated with pegylated interferon (PEG-IFN) and ribavirin (RBV). Methods: Data were retrieved fromMedline, Embase, PubMed and the Cochrane Library for ‘genotype 6' studies published up to December 2014 and for abstracts from international scientific meetings. Inclusion criteria were efficacy of PEG-IFN+RBV based on SVR, 24- or 48-week therapy and treatment-naïve patients. Patients with hepatitis B, D and E and HIV coinfection or another concurrent liver disease were excluded. Pooled standard difference, odds ratio and confidence intervals (CIs) were calculated using a random-effect model with STATA 11. Results: Fourteen studies were included in the meta-analysis. The pooled SVR rate was 80% (95% CI: 0.78-0.83, p < 0.0001; I² = 71.2%). SVR of the PEG-IFN+RBV-treated HCV-6 patients was markedly higher than that of HCV-1 patients (80.1 vs. 55.3%). The SVR rate was significantly higher for the 48- than the 24-week treatment, but not different among HCV-infected patients with rs12979860 and ss469415590 polymorphisms of the ILFN4 gene (80.6% CC vs. 66.7% non-CC, p = 0.593; 81.1% TT/TT vs. 60% non-TT/TT, p = 0.288). Gender and type of PEG-IFN did not affect SVR rates. Conclusions: Treatment outcomes for HCV-6 patients are superior to those for HCV-1 patients and comparable to those of HCV-2 and HCV-3 patients, especially at 48 weeks. The level of fibrosis affects treatment outcome, but SVR rates are not significantly different between genders. IL28B and IFNL4 polymorphisms are not significantly associated with HCV-6 treatment outcome.

show abstract

“…The geographic proximity to Southeast Asia and presence of drug trafficking and use likely explains route of entry of genotype 6a into the Guangdong province. The [46]. In vitro studies on efficacy of novel protease inhibitors (PI) on genotype 6a have also demonstrated good response [47], and a limited but promising U.S.-based phase 2 clinical trial on genotype 6 patients demonstrated all five HCV genotype 6 patients enrolled achieving SVR on 24 weeks of sofosbuvir in combination with peg-interferon and ribavirin [48].…”

Section: Discussionmentioning

confidence: 99%

Genotypic distribution and hepatic fibrosis among HIV/HCV coinfected individuals in southern China: A retrospective cross-sectional study

Zhou

Wang

et al. 2015

Journal of Clinical Virology

View full text Add to dashboard Cite

Background: End-stage liver disease and hepatocellular carcinoma due to hepatitis C virus (HCV) co-infection are increasingly common causes of death among HIV-infected individuals. However, there are few clinical investigations of HIV/HCV co-infected individuals from low and middle-income nations. Here, we compare the epidemiology of HCV-infected and HIV/HCV co-infected individuals in Southern China and examine hepatic fibrosis scores in co-infected individuals. Methods: We conducted a retrospective cross-sectional study of treatment-naïve HIV/HCV co-infected and HCV mono-infected subjects. Bivariate and multivariate models were used to examine the association between demographics and HCV genotype. Among co-infected individuals, we also studied the relationship between fibrosis scores derived from non-invasive studies and HCV genotype. Results: Data were collected from 175 HCV-infected individuals, including 89 (51 %) HIV/HCV co-infected individuals. HIV/HCV co-infection was correlated with intravenous drug use (AOR 46.25, p < 0.001) and not completing high school (AOR 17.39, p < 0.001) in a multivariate model. HIV/HCV co-infected individuals were more likely to be infected with HCV genotype 6a (p < 0.0001) or 3a (p < 0.023), whereas increased fibrosis (FIB-4 score) was associated with HCV genotype 3a infection (β 2.18, p < 0.001). Discussion: Our results suggest that intravenous drug use is driving HIV/HCV co-infection in Southern China. While additional studies are needed, HCV genotype 6a is more common and genotype 3a appears to be associated with more severe hepatic fibrosis in co-infected individuals. Conclusions: Future HIV/HCV co-infection research in China should focus on at risk populations, HCV testing uptake, and genotype-specific treatment.

show abstract

Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a

Cited by 19 publications

References 22 publications

Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population

Study of PKRBD in HCV genotype 3a infected patients in response to interferon therapy in Pakistani population

Influence of Host and Viral Factors on Patients with Chronic Hepatitis C Virus Genotype 6 Treated with Pegylated Interferon and Ribavirin: A Systematic Review and Meta-Analysis

Genotypic distribution and hepatic fibrosis among HIV/HCV coinfected individuals in southern China: A retrospective cross-sectional study

Contact Info

Product

Resources

About